MD Anderson
SBNET
2
Transcriptional immune characterization of the small bowel neuroendocrine tumor (SBNET) microenvironment
n=36
Age, median, range
63 (45-75)
• SBNET patients often present with metastatic disease; besides palliative surgery, there are very few good systemic therapeutic options (including immunotherapy) • Little is understood about the immune milieu of the SBNET tumor microenvironment and the potential signals that predict clinical outcomes and response
Sex
Female
13 (36%)
Male
23 (64%)
T Stage at Operation
T2
2 (5%)
T3
28 (78%)
T4
5 (14%)
Unknown
1 (3%)
N Stage at Operation
N0
5 (14%)
N1
26 (72%)
Study Aim
N2
3 (8%)
Determine the characteristics and transcriptional profiles of the SBNET tumor and immune microenvironment in
Unknown
2 (5%)
M Stage at Operation
M0
7 (19%)
M1
29 (81%)
order to identify predictive and potentially therapeutic targets for immunomodulation
Known History of Carcinoid Syndrome
Yes
14 (39%)
No
22 (61%)
Made with FlippingBook - professional solution for displaying marketing and sales documents online